*definitely* time to start to try and find out what Pivanex is..... Miljenko, if I've missed something that you've already posted (or forgotten something that I did........ :-), my apologies.......
Br J Cancer 1997;75(6):850-4
An anti-cancer derivative of butyric acid (pivalyloxmethyl buterate) and
daunorubicin cooperatively prolong survival of mice inoculated with
monocytic leukaemia cells.
Kasukabe T, Rephaeli A, Honma Y
Department of Chemotherapy, Saitama Cancer Research Institute, Ina, Japan.
A derivative of butyric acid, pivalyloxymethyl butyrate (AN-9), inhibited the proliferation and induced apoptosis of mouse
monocytic leukaemia Mm-A cells, although sodium butyrate, but not AN-9, induced differentiation of the cells. AN-9 and
DNA-specific antineoplastic agents synergistically inhibited the growth of Mm-A cells, and the simultaneous treatment was
required to evoke the maximum growth-inhibitory effect. On the other hand, there was no synergy between butyrate and the
drugs, or AN-9 and anti-metabolic agents in inhibiting the growth of the cells, suggesting that the synergistic effect is specific to
AN-9 and DNA-reacting agents. AN-9 as a single agent prolonged the survival of mice inoculated with Mm-A cells in a
dose-dependent manner. Moreover, administration of AN-9 plus daunorubicin (DNR) markedly prolonged their survival.
These results suggest that combination with AN-9 and DNR entails an obvious therapeutic potential. |
